Gilead Sciences Wins California Supreme Court Case on 'Duty to Innovate'

California's highest court has ruled in favor of Gilead Sciences in a landmark case, finding that the biopharmaceutical company did not have a legal duty to develop and release a safer alternative to its successful HIV medication on a specific timeline. The decision dismisses negligence claims brought by an estimated 24,000 patients.

The Court's Decision

In a 6-1 decision on Monday, the California Supreme Court reversed a lower court's ruling, effectively ending the litigation against Gilead. The majority opinion, written by Justice Joshua Groban, stated that imposing liability for a "concededly nondefective drug" because a different drug was not made available sooner would establish a dangerous precedent.

Justice Groban wrote that recognizing such a "duty to innovate" would create "sweeping liability" and risk "adverse consequences for pharmaceutical innovation, public health, and patient safety." The court argued that this could create substantial burdens on manufacturers and disincentivize the development of new treatments.

Background of the Dispute

The case centered on two of Gilead's HIV treatments:

Ad

• TDF (tenofovir disoproxil fumarate): An effective drug approved in 2001 but known to have potential side effects, including kidney and bone density issues.
• TAF (tenofovir alafenamide fumarate): A newer compound with a similar mechanism but fewer of the same side effects.

Plaintiffs alleged that Gilead deliberately delayed the development of TAF, which it began testing shortly after TDF's approval but halted in 2004. They claimed the company paused the safer drug's development to maximize profits from TDF before its patent exclusivity expired in 2017. Gilead countered that it initially concluded TAF's safety and effectiveness were not different enough from TDF to justify the expense of further development at the time.

Implications for the Pharmaceutical Industry

The ruling is a significant victory for Gilead and the broader pharmaceutical industry, which had closely monitored the case. The concept of a legal "duty to innovate" raised concerns among drugmakers that they could be penalized for the commercial success of existing products, potentially stifling research and development by making it prohibitively expensive and risky.

In a statement, Gilead said the decision "is a victory for all those working to develop improved medical treatments and new medicines" and that it "supports American innovation." The case highlighted the high financial stakes involved, as HIV drugs accounted for 70% of Gilead's $29.4 billion revenue in 2025, according to the source material.